HC Wainwright Reiterates Buy Rating for Vanda Pharmaceuticals (NASDAQ:VNDA)

Vanda Pharmaceuticals (NASDAQ:VNDA)‘s stock had its “buy” rating restated by equities research analysts at HC Wainwright in a research note issued on Thursday,Benzinga reports. They presently have a $20.00 target price on the biopharmaceutical company’s stock. HC Wainwright’s target price suggests a potential upside of 321.05% from the stock’s current price.

A number of other analysts have also recently weighed in on the stock. Cantor Fitzgerald reissued an “overweight” rating and set a $13.00 price objective on shares of Vanda Pharmaceuticals in a report on Wednesday, May 14th. Wall Street Zen cut shares of Vanda Pharmaceuticals from a “hold” rating to a “strong sell” rating in a report on Saturday, August 2nd. One investment analyst has rated the stock with a Strong Buy rating and one has assigned a Buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Strong Buy” and an average target price of $16.50.

Vanda Pharmaceuticals Trading Up 5.3%

VNDA stock opened at $4.75 on Thursday. Vanda Pharmaceuticals has a twelve month low of $3.81 and a twelve month high of $5.55. The company’s 50 day moving average is $4.61 and its two-hundred day moving average is $4.53. The stock has a market cap of $280.68 million, a P/E ratio of -4.20 and a beta of 0.72.

Vanda Pharmaceuticals (NASDAQ:VNDA) last released its quarterly earnings data on Thursday, July 31st. The biopharmaceutical company reported ($0.46) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.12). Vanda Pharmaceuticals had a negative return on equity of 12.89% and a negative net margin of 32.90%.The company had revenue of $52.59 million for the quarter, compared to analyst estimates of $54.77 million. Vanda Pharmaceuticals has set its FY 2025 guidance at EPS. On average, equities research analysts predict that Vanda Pharmaceuticals will post -1.12 earnings per share for the current year.

Insider Activity at Vanda Pharmaceuticals

In other Vanda Pharmaceuticals news, Director Stephen Ray Mitchell sold 7,000 shares of the business’s stock in a transaction on Friday, June 13th. The shares were sold at an average price of $4.59, for a total transaction of $32,130.00. Following the sale, the director directly owned 97,082 shares in the company, valued at approximately $445,606.38. The trade was a 6.73% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 10.00% of the company’s stock.

Institutional Investors Weigh In On Vanda Pharmaceuticals

Several institutional investors have recently made changes to their positions in VNDA. CWM LLC boosted its position in shares of Vanda Pharmaceuticals by 424.6% during the 2nd quarter. CWM LLC now owns 9,359 shares of the biopharmaceutical company’s stock worth $44,000 after purchasing an additional 7,575 shares in the last quarter. Quantinno Capital Management LP purchased a new stake in shares of Vanda Pharmaceuticals during the 4th quarter worth $48,000. PVG Asset Management Corp purchased a new stake in shares of Vanda Pharmaceuticals during the 1st quarter worth $48,000. Linden Thomas Advisory Services LLC purchased a new stake in shares of Vanda Pharmaceuticals during the 1st quarter worth $49,000. Finally, Nations Financial Group Inc. IA ADV purchased a new stake in shares of Vanda Pharmaceuticals during the 1st quarter worth $67,000. 88.14% of the stock is currently owned by hedge funds and other institutional investors.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.